Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus

By Pandya Bhavik J.   Bron Morgan   McCall Therese   Yu Andrew P.   Chen Kristina S.   Mattson Miles E.   Wu Eric Q.  

Current Medical Research and Opinion, Vol. 27, Iss. 1, 2011-01 ,pp. : 189-195

Informa Healthcare

Access to resources Recommend Favorite

Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial

By Umpierrez Guillermo   Issa Maher   Vlajnic Aleksandra  

Current Medical Research and Opinion, Vol. 22, Iss. 4, 2006-04 ,pp. : 751-759

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double‐blind, active‐controlled, phase 3 trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 590-598

John Wiley & Sons Inc

Access to resources Recommend Favorite

Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide

By Schwartz Stanley  

Current Medical Research and Opinion, Vol. 24, Iss. 11, 2008-11 ,pp. : 3009-3022

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study

By Williams-Herman Debora   Johnson Jeremy   Teng Rujun   Luo Edmund   Davies Michael J.   Kaufman Keith D.   Goldstein Barry J.   Amatruda John M.  

Current Medical Research and Opinion, Vol. 25, Iss. 3, 2009-03 ,pp. : 569-583

Informa Healthcare

Access to resources Recommend Favorite